20102019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Editorial
Editorial

Brain imaging in early stage non-small cell lung cancer: still a controversial topic?

Schoenmaekers, J. J. A. O., Dingemans, A-M. C. & Hendriks, L. E. L., 1 Jul 2018, In : Journal of Thoracic Disease. 10, p. S2168-S2171 4 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment

Hendriks, L. E. L., Subramaniam, D. S. & Dingemans, A-M. C., 6 Nov 2018, In : Frontiers in Oncology. 8, 3 p., 511.

Research output: Contribution to journalEditorialAcademicpeer-review

Open Access

Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?

Dingemans, A-M. C. & Hendriks, L. E. L., Apr 2019, In : The Lancet Respiratory medicine. 7, 4, p. 291-292 2 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?

Hendriks, L. E. L. & Dingemans, A-M. C., Mar 2019, In : Lung Cancer. 129, p. 95-97 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle

Derks, J., Speel, E., Thunnissen, E., van Suylen, R. J., Buikhuisen, W. A., van Velthuysen, M-L. & Dingemans, A-M., Mar 2016, In : Journal of Thoracic Oncology. 11, 3, p. e35-e38 7 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Open Access
4 Citations (Scopus)

PD-(L)1 Inhibition and Cardiac Damage: A Relevant Toxicity?

De Ruysscher, D., Dingemans, A-M., Vooijs, M. & Heymans, S., 1 Apr 2018, In : Journal of Thoracic Oncology. 13, 4, p. 478-479 2 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

Mountzios, G., Remon, J., Novello, S., Blais, N., Califano, R., Cufer, T., Dingemans, A. M., Liu, S. V., Peled, N., Pennell, N. A., Reck, M., Rolfo, C., Tan, D., Vansteenkiste, J., West, H. & Besse, B., Nov 2019, In : Annals of Oncology. 30, 11, p. 1686-1688 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

The Optimal Local Treatment of Stage IIIA-N2 NSCLC: Is the Issue Finally Settled?

De Ruysscher, D., Vansteenkiste, J., Belderbos, J., Decaluwe, H. & Dingemans, A-M., Mar 2016, In : Journal of Thoracic Oncology. 11, 3, p. 284-286 3 p.

Research output: Contribution to journalEditorialAcademicpeer-review

Open Access
2 Citations (Scopus)